The World's Greatest Investing Community
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
I've never been a believer in Derma so I'll fling myself onto this rising knife. There's no consistent upward trend in quarterly revenues and the company seems to be dragging their heels on a phase III trial of DSC127. Could that be because the FDA wants an active comparator instead of placebo and the company knows they won't get stat sig in ulcer healing with that approach? Meanwhile, the dilution continues.
As I've said before, I don't grudge Derma 100M in enterprise value. Above that I start getting skeptical.